Essential Pharma News Today

Essential Pharma Acquires Renaissance Pharma Ltd with Its Clinical Stage Immunotherapy for the Treatment of High-risk Neuroblastoma

Essential Pharma acquires Renaissance Pharma Ltd with its clinical stage immunotherapy for the treatment of high-risk neuroblastoma

Essential Pharma acquires European rights to Colobreathe®(colistimethate sodium) from Teva

Essential Pharma Announces the Appointment of Emma Johnson as Chief Executive Officer Zug, Switzerland & Egham, UK - 24 May 2023 - Essential Pharma, an international specialty pharma company focused

UK marketing authorisations for IOPIDINE® (apraclonidine) fully transferred to Essential Pharma as change in UK NICE guidelines for glaucoma treatment...

UK marketing authorisations for IOPIDINE (apraclonidine) fully transferred to Essential Pharma as change in UK NICE guidelines for glaucoma treatment expected to lead to increase in patients' need

Essential Pharma Announces the Acquisition of HALDOL HALDOL is a first-generation 'typical' antipsychotic for the treatment of schizophrenia and some other psychiatric conditions The acquisition

This article reviews the application of competition law principles to the pharmaceutical sector in United Kingdom, with particular regard to the merger control regime and anticompetitive behaviour.

Essential Pharma, an international speciality pharma group focused on maintaining access to well-established, “at risk” products essential to patients across multiple therapeutic areas, announces the strengthening of its operating platform to support the next phase of its growth, with the granting of new ...

EGHAM, England, Aug. 25, 2022 /PRNewswire/ -- Essential Pharma, an international speciality pharma group focused on maintaining access to well-established, "at risk" products essential to patients